Quantcast

BIOQUAL Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of an mRNA Vaccine Against COVID-19 (mRNA-1273)

ROCKVILLE, Md.–(BUSINESS WIRE)–BIOQUAL announces the publication of the successful testing of an mRNA vaccine in non-human primates. The candidate vaccine, mRNA-1273, was co-developed by scientists at the NIAID Vaccine Research Center and a pharmaceutical company. The animal studies were performed at BIOQUAL. The results were published online in the New England Journal of Medicine. This project has been funded in whole or in part with Federal funds from the NIAID, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00069

Article

KS Corbett et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. New England Journal of Medicine DOI: 10.1056/NEJMoa2024671 (2020).

About BIOQUAL

BIOQUAL has been engaged in development of in-vivo testing programs and has been extensively involved in research efforts to develop vaccines and therapies against emerging diseases including AIDS, Hepatitis, Zika, Chikungunya and many others. The company is now focused on COVID-19 research and is positioned to play an important role in the development of successful vaccines and therapies against this epidemic.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

(Read more…)

Contacts

Mark G. Lewis, Ph.D., CEO (240-404-7654)

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.